GleamWall
中文EN

GTBP GT Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 109657 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-309.0%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,446.5%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets—
Debt / equity0.00x
Current ratio4.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.71M$1.05M$413,000$1.38M$634,000$363,000$1.10M$1.93M
SG&A expense$1.80M$3.46M$2.44M$4.22M$2.75M$1.15M$833,000$1.83M
Operating income-$3.51M-$4.51M-$2.85M-$5.59M-$3.38M-$1.51M-$1.93M-$3.76M
Interest expense$63,000$64,000$63,000—————
Net income-$3.53M-$4.52M-$2.83M-$23.03M$8.30M-$30.17M-$776,000-$3.77M
EPS (basic)-1.98-0.12-0.11—25.99-10.92-0.33—
EPS (diluted)-1.98-0.12-0.11—25.99-10.92-0.33—
Weighted avg. shares (diluted)1.81M38.82M30.28M—157,6292.77M2.35M—
Balance sheet
Cash & equivalents$9.92M$4.96M$8.92M$6.81M$2.62M$5.32M$2.46M$4.04M
Current assets$10.57M$5.79M$10.00M$8.11M$4.32M$7.12M$2.66M$4.23M
Total assets———$8.11M$4.32M$7.12M—$4.23M
Current liabilities$2.77M$2.22M$2.42M$2.32M$1.32M$31.04M$3.64M$5.90M
Total liabilities$2.77M$2.22M$2.42M$2.32M$1.32M$31.04M$3.64M$5.90M
Shareholders' equity$7.80M$3.57M$7.58M$5.79M$3.00M-$25.88M-$980,000-$1.67M
Shares outstanding2.06M44.67M35.18M1.02M6.05M3.27M2.54M2.23M
Cash flow statement
Operating cash flow-$2.64M-$4.26M-$2.47M-$4.02M-$3.68M-$3.01M-$2.20M-$2.47M
Investing cash flow———————$1,000
Financing cash flow$7.60M$297,000$4.58M$8.30M$977,000$5.88M$616,000$0
Stock-based compensation——$46,000$46,000$379,000$4,000$3,000$8,000
Dividends paid———$144,000————

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.